Compound assessment research support
Ended Definitive Contract Awarded Last action
- Contract number
- HT942523C0099
- Awardee
-
George Mason University UEI EADLFP7Z72E5 Part of The George Mason University Instructional Foundation, Inc.
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $741,236
Award facts
- Opportunity
-
- HT942523R0119 Solicitation number
- Contract value 100% obligated
- $741,236.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Not Competed · 1 offer Only One Source
- Pricing
- Firm Fixed Price
- Place of performance
- Silver Spring, MD 20910, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $97,897 | |
| Exercise an Option | $291,572 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $351,767 |
About this award
George Mason University was awarded a $741,236 firm fixed-price definitive contract by the Defense Health Agency on September 21, 2023, to conduct research supporting the defeat of combat-related wound infections affecting warfighters. The work will be performed in Silver Spring, Maryland, with an ultimate completion date of September 28, 2026. This contract was awarded on a competitive basis without any set-aside designation, reflecting George Mason University's established capabilities as a research institution supporting defense and health priorities through federal contracting.
The research effort includes a subcontract with Covenant Therapeutics LLC, a minority-owned small business specializing in biomedical research and therapeutic development. Under this three-year subcontract awarded in June 2024, Covenant Therapeutics will synthesize compound libraries to develop structure-activity relationships for peptide derivatives of CT-AP1, an antibiotic compound. The work encompasses designing second-generation analogs with improved antimicrobial activity and producing large quantities of three lead compounds for in vivo studies, directly supporting the prime contract's objective of developing therapeutic solutions for combat-related wound infection management.
Subawards
| Subcontractor | Amount | Awarded |
|---|---|---|
| Covenant Therapeutics LLC | $186,428 |
Quick answers
Who was awarded contract HT942523C0099?
HT942523C0099 was awarded to George Mason University by Defense Health Agency (Department of Defense) on September 21, 2023.
How much is contract HT942523C0099 worth?
The government has obligated $741,236 on HT942523C0099.
Was contract HT942523C0099 competed?
The extent of competition for HT942523C0099 was not competed. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award